Rapid Policy Statement

Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19

Published on: 24 December 2021
Updates highlighted in yellow

Commissioning position

The proposal is: Sotrovimab is recommended to be available as a treatment option through routine commissioning for non-hospitalised adults and children (aged 12 years and above) with COVID-19 treated in accordance with the criteria set out in this document. Where treatment with sotrovimab is contraindicated or not possible, eligible patients may be offered an antiviral as an alternative.

Background

nMABs are synthetic monoclonal antibodies that bind to the spike protein of SARS-CoV-2, preventing subsequent entry of the virus into the host cell and its replication. This effectively ‘neutralises’ the virus particle. The following nMAB has conditional marketing authorisation (or regulation 174 emergency use authorisation in Northern Ireland) for use in the treatment of COVID-19 in the UK:

- Sotrovimab (Xevudy®): a dual-action nMAB that both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2

Recent evidence suggests that nMABs and oral antivirals significantly improve clinical outcomes in unvaccinated\(^1\) non-hospitalised patients with COVID-19 who are at high risk of progression to severe disease and/or death. Key findings are as follows:

- Sotrovimab administered intravenously to non-hospitalised patients with mild-to-moderate disease and at least one risk factor for disease progression resulted in a relative risk reduction in hospitalisation or death by 85% (Gupta et al, 2021).

\(^1\) This evidence has only been collected in unvaccinated populations – further research on vaccinated populations is needed.
• Final results from the Phase 3 MOVe-OUT trial show that the oral antiviral molnupiravir resulted in a relative risk reduction of 30% in the composite primary outcome of hospitalisation or death at day 29 (Bernal et al, 2021).

Marketing authorisation

Sotrovimab
Sotrovimab delivered intravenously has conditional marketing authorisation in Great Britain (England, Scotland and Wales) for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19 infection. Access to sotrovimab in Northern Ireland for the above indication is through a Regulation 174 approval or a licensing determination by the European Medicines Agency.

Molnupiravir
Molnupiravir administered orally has conditional marketing authorisation in Great Britain (England, Scotland and Wales) for use in the treatment of mild to moderate COVID-19 in adults (aged 18 years and over) with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. Access to molnupiravir in Northern Ireland for this indication is through a Regulation 174 approval or a licensing determination by the European Medicines Agency.

Eligibility criteria
Patients must meet all of the eligibility criteria and none of the exclusion criteria. Pre-hospitalised patients are eligible for treatment if:

• SARS-CoV-2 infection is confirmed by polymerase chain reaction (PCR) testing within the last 5 days
  AND

• Onset of symptoms of COVID-19 within the last 5 days
  AND

• A member of a ‘highest’ risk group (as defined in Appendix 1).

The eligible patients as outlined in this policy should initially be considered for treatment with an nMAB (sotrovimab). Where an nMAB is contraindicated or the administration of an nMAB is not possible, patients may be treated with a five-day course of molnupiravir if the onset of symptoms is in the last 5 days.

Patients who have received an nMAB within a post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP) trial (such as the PROTECT-V trial) who meet the eligibility criteria of this policy can still receive treatment with an nMAB.

---

2 For paediatric/adolescent patients (aged 12-17 years inclusive), paediatric multi-disciplinary team (MDT) assessment should be used to determine clinical capacity to benefit from the treatment

3 The following are considered symptoms of COVID-19: feverish, chills, sore throat, cough, shortness of breath or difficulty breathing, nausea, vomiting, diarrhoea, headache, red or watery eyes, body aches, loss of taste or smell, fatigue, loss of appetite, confusion, dizziness, pressure or tight chest, chest pain, stomach ache, rash, sneezing, sputum or phlegm, runny nose

4 For patients who have been symptomatic (within the specified time period) but are no longer symptomatic, clinical judgement should determine suitability for treatment
Exclusion criteria
Patients are not eligible for nMAB treatment in the community if they meet any of the following:

- The pattern of clinical presentation indicates that there is recovery rather than risk of deterioration from infection
- Require hospitalisation for COVID-19
- New supplemental oxygen requirement specifically for the management of COVID-19 symptoms
- Children weighing less than 40kg
- Children aged under 12 years
- Known hypersensitivity reaction to the active substances or to any of the excipients of sotrovimab as listed in the respective Summary of Product Characteristics

Serology testing
Where possible, all patients should have samples taken for serology testing against SARS-CoV-2 prior to treatment with an nMAB. However, serology results are not a requirement for treatment with nMABs under the criteria specified in this policy.

Cautions
Please refer to the Summary of Product Characteristics (SmPC) for sotrovimab and molnupiravir for special warnings and precautions for use.

Sotrovimab
Hypersensitivity reactions, including serious and/or life-threatening reactions such as anaphylaxis, have been reported following infusion of sotrovimab. Hypersensitivity reactions typically occur within 24 hours of infusion. Signs and symptoms of these reactions may include nausea, chills, dizziness (or syncope), rash, urticaria and flushing. If signs and symptoms of severe hypersensitivity reactions occur, administration should be discontinued immediately and appropriate treatment and/or supportive care should be initiated.

If mild to moderate hypersensitivity reactions occur, slowing or stopping the infusion along with appropriate supportive care should be considered.

Molnupiravir
The most common adverse reactions (≥1% of subjects) reported during treatment and during 14 days after the last dose of molnupiravir were diarrhoea (3%), nausea (2%), dizziness (1%) and headache (1%) all of which were Grade 1 (mild) or Grade 2 (moderate).

COVID-19 vaccines
Concomitant administration of an nMAB with COVID-19 vaccines has not been studied. Refer to local/national guidelines for vaccine administration and guidance on the risks associated with administration of a SARS-CoV-2 vaccine.

Further information on the timing of COVID-19 vaccination following administration of an nMAB is available at the following sites:

- Liverpool COVID-19 Interactions (covid19-druginteractions.org)

---

5 Molnupiravir is only licensed for adults aged 18 years and above.
• Interactions information for COVID-19 vaccines – SPS – Specialist Pharmacy Services

Pregnancy and women of childbearing potential

There are no data from the use of sotrovimab in pregnant women. The SmPC for sotrovimab states that sotrovimab may be used during pregnancy where the expected benefit to the mother justifies the risk to the foetus.

There are no data from the use of molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity. Molnupiravir is not recommended during pregnancy. Individuals of childbearing potential should use effective contraception for the duration of treatment and for 4 days after the last dose of molnupiravir. All healthcare professionals are asked to ensure that any patients who receive a COVID antiviral while pregnant are reported to the UK COVID-19 antivirals in pregnancy registry on 0344 892 0909 so that they can be followed up. For more information go to http://www.uktis.org/. Clinicians are advised to refer to the SmPC for molnupiravir for more information on use during pregnancy or lactation.

Dose and administration

Sotrovimab

The recommended dose of sotrovimab is 500mg to be administered as a single intravenous infusion. 8mls of sotrovimab (62.5mg/ml) should be added to a 100ml pre-filled infusion bag containing 0.9% sodium chloride and administered over 30 minutes.

Preparation and administration of sotrovimab should be initiated and monitored by a qualified healthcare provider using aseptic technique. Administration should be under conditions where management of severe hypersensitivity reactions, such as anaphylaxis, is possible. Individuals should be monitored post intravenous infusion according to local medical practice.

Refer to the Specialist Pharmacy Services institutional readiness document for further information on the handling, reconstitution and administration of the product.

Sotrovimab should not be infused concomitantly in the same intravenous line with other medication.

Molnupiravir

The recommended dose of molnupiravir is 800mg (four 200mg capsules) taken orally every 12 hours for 5 days. Treatment must not be extended beyond 5 days. Molnupiravir should be commenced as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.

To reduce the possibility of emerging resistance, patients should be advised to complete the whole course of treatment even if their symptoms improve and/or they feel better.

Co-administration

There is no interaction expected between sotrovimab or molnupiravir with the drugs listed below. For further information please visit the University of Liverpool COVID-19 Drug Interactions website (https://www.covid19-druginteractions.org/checker).

Corticosteroids

6 No dose adjustment is recommended in patients with renal or hepatic impairment.
Administration of systemic dexamethasone or hydrocortisone is recommended in the management of patients with severe or critical COVID-19. Corticosteroids are not suggested in non-severe COVID-19 disease. Updated WHO guidance on the use of systemic corticosteroids in the management of COVID-19 can be found here. nMABs and antivirals should not be regarded as an alternative to corticosteroids.

**Remdesivir**

The Clinical Commissioning Policy for the use of remdesivir in hospitalised patients with COVID-19 can be found here.

**IL-6 inhibitors**

The Clinical Commissioning Policies for the use of IL-6 inhibitors in hospitalised patients with COVID-19 who require supplemental oxygen can be found here.

**Safety reporting**

It is vital that any suspected adverse reactions (including congenital malformations and/or neurodevelopmental problems following treatment during pregnancy) are reported directly to the MHRA via the new dedicated COVID-19 Yellow Card reporting site at: https://coronavirus-yellowcard.mhra.gov.uk/.

**Governance**

**Data collection requirement**

Provider organisations in England should register all patients using prior approval software (alternative arrangements in Scotland, Wales and Northern Ireland will be communicated) and ensure monitoring arrangements are in place to demonstrate compliance against the criteria as outlined.

Clinicians are also required to ensure that any data collection requirements are met for the purpose of ongoing surveillance, audit and relevant research around the use of nMABs and antivirals (see ‘Research’ section below).

**Clinical outcome reporting**

Where available, hospitals managing COVID-19 patients are strongly encouraged to submit data through the ISARIC 4C Clinical Characterisation Protocol (CCP) case report forms (CRFs), as coordinated by the COVID-19 Clinical Information Network (CO-CIN) (https://isaric4c.net/protocols/).

**Effective from**

This policy will be in effect from the date of publication.

**Policy review date**

This is an interim rapid clinical policy statement, which means that the full process of policy production has been abridged: public consultation has not been undertaken. This policy may need amendment and updating if, for instance, new trial data emerges, supply of the drug changes, or a new evidence review is required. A NICE Technology Appraisal or Scottish Medicines Consortium (SMC) Health Technology Assessment or All Wales Medicines Strategy Group (AWMSG) appraisal of nMABs and/or antivirals for COVID-19 would supersede this policy when completed.
This policy will be reviewed, if required, as further data emerge on the population prevalence of the omicron variant and any impact it may have on the efficacy of COVID-19 therapies.

**Surveillance and service evaluation**

There is an urgent need to generate more evidence and greater understanding around the use of nMABs and antivirals in the treatment of patients with COVID-19. Both surveillance and service evaluation are necessary to gain knowledge around the following: factors of relevance in determining nMAB and antiviral treatment; the impact of nMAB and antiviral treatment in the community and hospital settings on the immune/virologic response and clinical recovery; and the public health sequelae of nMAB and antiviral use, such as generation of new mutations.

Treating clinicians are asked to ensure that all PCR tests undertaken as an inpatient and/or in the community where any patient who is receiving ongoing PCR testing as part of secondary care (for example, through an outpatient clinic) should do this through the hospital laboratory where these samples should be retained for sequencing. Further serial sampling for specific patient groups may be requested as part of UKHSA genomic surveillance purposes, or country specific programmes.

Clinicians must ensure that any additional data collection requirements are met for the purpose of relevant surveillance, audit and evaluation around the use of nMABs and antivirals. It is expected that there will be ongoing monitoring (involving sample collection) of selected patients treated with nMABs and antivirals (led by UKHSA, for instance around the potential generation of new variants), as well as academic research to generate new knowledge around clinical effectiveness and other relevant aspects of public health.

**Equality statement**

Promoting equality and addressing health inequalities are at the heart of the four nations’ values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010 or equivalent equality legislation) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities.

**Definitions**

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>Refers to the disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus</td>
</tr>
<tr>
<td>Neutralising monoclonal antibody</td>
<td>Synthetic antibodies that bind to a virus and inhibit its ability to infect host cells and replicate</td>
</tr>
<tr>
<td>Spike protein</td>
<td>The part of the SARS-CoV-2 virus that binds to the host cell, which then facilitates its entry into the cell</td>
</tr>
</tbody>
</table>
References


Appendix 1: Patient cohorts considered at highest risk from COVID-19 and to be prioritised for treatment with nMABs

The following patient cohorts were determined by an independent advisory group commissioned by the Department of Health and Social Care (DHSC)⁷.

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Down’s syndrome</td>
<td>All patients with Down’s syndrome</td>
</tr>
</tbody>
</table>
| Patients with a solid cancer                                           | • Active metastatic cancer and active solid cancers (at any stage)  
  • All patients receiving chemotherapy within the last 3 months  
  • Patients receiving group B or C chemotherapy 3-12 months prior (see Appendix 2)  
  • Patients receiving radiotherapy within the last 6 months |
| Patients with a haematological diseases and stem cell transplant recipients | • Allogeneic haematopoietic stem cell transplant (HSCT) recipients in the last 12 months or active graft vs host disease (GVHD) regardless of time from transplant (including HSCT for non-malignant diseases)  
  • Autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases)  
  • Individuals with haematological malignancies who have  
    • received chimaeric antigen receptor (CAR)-T cell therapy in the last 24 months, or  
    • radiotherapy in the last 6 months  
  • Individuals with haematological malignancies receiving systemic anti-cancer treatment (SACT) within the last 12 months except patients with chronic phase chronic myeloid leukaemia (CML) in molecular response or first or second line tyrosine kinase inhibitors (TKI).  
  • All patients with myeloma (excluding MGUS) or chronic B-cell lymphoproliferative disorders (e.g. chronic lymphocytic leukaemia, follicular lymphoma) or myelodysplastic syndrome (MDS) who do not fit the criteria above.  
  • All patients with sickle cell disease.  
  • Individuals with non-malignant haematological disorder (e.g. aplastic anaemia or paroxysmal nocturnal haemoglobinuria) receiving B-cell depleting systemic treatment (e.g. anti-CD20, anti-|

⁷ For paediatric/adolescent patients (aged 12-17 years inclusive), paediatric multi-disciplinary team (MDT) assessment should be used to determine clinical capacity to benefit from the treatment.
| Patients with renal disease | • Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who:  
  o Received B cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], anti-thymocyte globulin)  
  o Have an additional substantial risk factor which would in isolation make them eligible for nMABs or oral antivirals  
  o Not been vaccinated prior to transplantation  
• Non-transplant patients who have received a comparable level of immunosuppression  
• Patients with chronic kidney stage (CKD) 4 or 5 (an eGFR less than 30 ml/min/1.73m²) without immunosuppression |
| Patients with liver disease | • Patients with cirrhosis Child's-Pugh class B and C (decompensated liver disease).  
• Patients with a liver transplant  
• Liver patients on immune suppressive therapy (including patients with and without liver cirrhosis)  
• Patients with cirrhosis Child's-Pugh class A who are not on immune suppressive therapy (compensated liver disease) |
| Patients with immune-mediated inflammatory disorders (IMID) | • IMID treated with rituximab or other B cell depleting therapy in the last 12 months  
• IMID with active/unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate.  
• IMID with stable disease on either corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate.  
• IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate |
| Primary immune deficiencies | • Common variable immunodeficiency (CVID)  
• Undefined primary antibody deficiency on immunoglobulin (or eligible for Ig)  
• Hyper-IgM syndromes  
• Good's syndrome (thymoma plus B-cell deficiency)  
• Severe Combined Immunodeficiency (SCID)  
• Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) |
- Primary immunodeficiency associated with impaired type I interferon signalling
- X-linked agammaglobulinaemia (and other primary agammaglobulinaemias)

**HIV/AIDS**
- Patients with high levels of immune suppression, have uncontrolled/untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis
- On treatment for HIV with CD4 <350 cells/mm³ and stable on HIV treatment or CD4 >350 cells/mm³ and additional risk factors (e.g. age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, those with alcohol-dependence)

**Solid organ transplant recipients**
- All recipients of solid organ transplants not otherwise specified above

**Rare neurological conditions**
- Multiple sclerosis
- Motor neurone disease
- Myasthenia gravis
- Huntington’s disease
Appendix 2: Chemotherapy agents (Groups B and C)

Patients currently on or who have received the following chemotherapy regimens (Groups B and C in the table below) in the last 12 months and are considered to be at higher risk of Grade 3/4 febrile neutropenia or lymphopenia.

<table>
<thead>
<tr>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-50% risk of grade 3/4 febrile neutropenia or lymphopenia</td>
<td>&gt;50% risk of grade 3/4 febrile neutropenia or lymphopenia</td>
</tr>
<tr>
<td>• Etoposide based regimens</td>
<td>• All acute myeloid leukaemia/acute lymphocytic regimens</td>
</tr>
<tr>
<td>• CMF</td>
<td>• Bleomycin, etoposide and platinum</td>
</tr>
<tr>
<td>• Irinotecan and Oxaliplatin based regimens</td>
<td>• Highly immunosuppressive chemotherapy (e.g. FluDAP, high dose Methotrexate &amp; Cytarabine)</td>
</tr>
<tr>
<td>• Cabazitaxel</td>
<td>• Trifluradine/ Tipiracil</td>
</tr>
<tr>
<td>• Gemcitabine</td>
<td>• KTE-X19</td>
</tr>
<tr>
<td>• Chlorambucil</td>
<td>• Gilteritinib</td>
</tr>
<tr>
<td>• Temozolomide</td>
<td></td>
</tr>
<tr>
<td>• Daratumumab</td>
<td></td>
</tr>
<tr>
<td>• Rituximab</td>
<td></td>
</tr>
<tr>
<td>• Obinutuzumab</td>
<td></td>
</tr>
<tr>
<td>• Pentostatin</td>
<td></td>
</tr>
<tr>
<td>• Proteosome inhibitors</td>
<td></td>
</tr>
<tr>
<td>• IMIDs</td>
<td></td>
</tr>
<tr>
<td>• PI3Kinase inhibitors</td>
<td></td>
</tr>
<tr>
<td>• BTK inhibitors</td>
<td></td>
</tr>
<tr>
<td>• JAK inhibitors</td>
<td></td>
</tr>
<tr>
<td>• Venetoclax</td>
<td></td>
</tr>
<tr>
<td>• Trastuzumab-emtansine</td>
<td></td>
</tr>
<tr>
<td>• Anthracycline-based regimens</td>
<td></td>
</tr>
<tr>
<td>• Fluorouracil, epirubicin and cyclophosphamide (FEC)</td>
<td></td>
</tr>
<tr>
<td>• Methotrexate, vinblastine, adriamycin/doxorubicin, cisplatin (MVAC)</td>
<td></td>
</tr>
<tr>
<td>• Adriamycin/doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)</td>
<td></td>
</tr>
<tr>
<td>• Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)</td>
<td></td>
</tr>
<tr>
<td>• Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone (BEACOPP)</td>
<td></td>
</tr>
<tr>
<td>• Liposomal doxorubicin</td>
<td></td>
</tr>
<tr>
<td>• Taxane – 3-weekly</td>
<td></td>
</tr>
<tr>
<td>• Nab-paclitaxel</td>
<td></td>
</tr>
<tr>
<td>• Carboplatin-based regimens</td>
<td></td>
</tr>
<tr>
<td>• Ifosphamide-based regimens</td>
<td></td>
</tr>
<tr>
<td>• Bendamustine</td>
<td></td>
</tr>
<tr>
<td>• Cladribine</td>
<td></td>
</tr>
<tr>
<td>• Topotecan</td>
<td></td>
</tr>
<tr>
<td>• Cyclophosphamide/Fludarabine combinations</td>
<td></td>
</tr>
<tr>
<td>• Ifosphamide, carboplatin, etoposide (ICE)</td>
<td></td>
</tr>
<tr>
<td>• Gemcitabine, dexamethasone, cisplatin (GDP)</td>
<td></td>
</tr>
<tr>
<td>• Isatuximab</td>
<td></td>
</tr>
<tr>
<td>• Polatuzumab</td>
<td></td>
</tr>
<tr>
<td>• Acalabrutinib</td>
<td></td>
</tr>
</tbody>
</table>
- Dexamethasone, cytarabine, cisplatin (DHAP)
- Etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP)
- Cyclophosphamide, vincristine, doxorubicin, dexamethasone (CVAD)
- Dacarbazine-based regimens
- Lomustine
- Magalizumab
- Brentuximab vedotin
- Asparaginase-based regimens